

Lindsay Lai^{1,2}; Ian Wilson²; Robert Wilkinson²; Rajesh Odreda²; Simon Ashton³; Alan Barnes³; Neil Loftus³.
¹Manchester University, Manchester, UK; ²AstraZeneca, Alderley Park, UK; ³Shimadzu, Manchester, United Kingdom

Introduction

A major factor affecting pharmaceutical drug discovery is the ability to predict the human efficacy/safety of new chemical entities (NCEs) from preclinical discovery and development data. This is far from being a new problem but it remains a critical challenge in drug discovery process. Determining which animal species/model adequately predicts human metabolism, efficacy and side effects remains a complex concern. In this study, mass spectrometry-based metabolite profiling was used to identify changes in endogenous metabolite levels in several mouse cancer models including colorectal and non small cell lung cancer cell tumors using high accuracy MSn analysis.

Methods

Several human colon cancer cell lines (HCT116, SW-620, COLO205 and HT-29) together with NSCLC line (CALU6) were implanted into mice at 8-10 weeks. Samples were harvested at 33 and 35 days for colorectal tumors HCT116 and SW-620; 7-14 days for colorectal HT-29; 7, 14, 21 and 28 days for NSCLC tumor. 100mg of manually disaggregated tumor tissue was mixed with 1mL (50% acetonitrile in water) and sonicated for 5 min followed by 10 min centrifugation (17,900 rcf). Keeping the precipitated pellets, the supernatants were separated out and put in autosampler vials as the aqueous extract. To extract the non-polar analytes the pellets were mixed with 1mL (75% chloroform, 25% methanol) and sonicated for 5 min followed by 10 min centrifugation (17,900 rcf). Organic extracts were resuspended in 1ml methanol (4°C) and aliquoted into vials. The results are presented for the organic extracts (not the aqueous extracts).

Samples obtained from these animals were measured by LC/MS using a quadrupole ion trap-time of flight mass spectrometer (LC-MS-IT-TOF, Shimadzu Corporation) using data dependent acquisitions in electrospray ionization (ESI) in both positive and negative mode. To identify biologically significant compounds, high mass accuracy MS and MSn fragment ion information was used to identify the most likely candidate molecules. A pooled biological QC sample was injected throughout the sample batch analysis (interspersed between every 5 samples) and the sample batch run time was approximately 60 hours (run time 40 minutes for each sample; 90 samples injected as one batch).

Name	GPCho	Tyrosine	Phenylalanine	Tryptophan	Sphinganine	GPCho	GPCho	GPEtn	GPEtn
m/z (M+H)	RT (min)	RT (min)	RT (min)	RT (min)	RT (min)	RT (min)	RT (min)	RT (min)	RT (min)
165.0546	1.31	2.67	2.67	3.32	14.3	15.19	22.32	20.493	22.207
166.0863	2.47	Phenylalanine							
175.1190	1.32	Arginine							
182.0812	1.31	Tyrosine							
186.0700	1.32	Methoxyacetic acid							
208.0972	3.32	Tryptophan							
220.1179	3.23	Pantoic acid							
258.1101	1.16	sn-Glyco-3-phosphocholine							
268.1040	1.36	Adenosine							
282.7791	1.03	10-oxo-10-oxo-octadecanamide							
284.0883	1.50	Guanosine							
291.1299	1.06	lL-argininobuccinate							
298.0968	3.28	5-methylthioadenosine							
302.3054	14.30	Sphinganine							
310.1133	1.61	sn-3'-phosphoadenosine 3'-phosphate							
400.3021	1.50	D-Pantoic acid							
400.3085	1.65	l-10-oxo-10-oxo-octadecanamide							
496.3998	25.46	1-Palmitoyl-1-acylglycerol-3-phosphocholine							
502.2928	24.95	l-10-oxo-10-oxo-octadecanamide							
522.3554	22.99	l-10-oxo-10-oxo-octadecanamide							
523.0711	26.30	hexadecyl-2-acetyl-glycerol-3-phosphocholine							

Table 1.
 Pooled QC sample analysis was used to assess the performance of the system by repeatedly injecting the QC sample throughout the analytical run over a 47 hour period. The table highlights the response of several metabolites following repeated injection, this includes amino acids (for example tyrosine, phenylalanine, tryptophan) and lipid signals (GPCho; GPCho [14:0/0/0], GPCho [16:0/0/0], GPCho [20:4/0/0], GPEtn [20:4/0/0], GPEtn [18:1/0/0]).

	1.064	5.576	5.704	6.369	3.815	3.01	1.595	2.037	1.949
Maximum	177,634.189	35,698.287	100,719.378	27,604.07	9,880.487	9,203.614	157,403.460	124,481.110	110,062.146
Minimum	171,400.811	29,530.407	82,333.777	21,752.309	8,503.786	8,328.164	149,327.341	114,907.738	100,763.221
Std. Dev.	1,853.388	1,787,810.26	5,171,768.16	1,547,052.85	303,505.90	262,851	2,448.193	2,434.369	2,024.768
Average	174,327.841	32,080.727	90,676.121	24,291.337	9,154.737	8,733.585	153,456.946	119,510.175	106,432.895

Results

m/z (M+H)	Ion RT	Metabolite	Avg SW	Avg HCT	Avg HT	Avg COLO	Avg Calu
165.0546	1.31	Arginine	2,802,390	3,550,220	11,424,893	9,475,129	4,376,829
166.0863	2.47	Phenylalanine	4,584,292	5,449,732	16,880,057	10,075,245	6,079,314
175.1190	1.32	Arginine	36,821,650	51,552,829	143,667,334	92,345,081	55,244,622
182.0812	1.31	Tyrosine	986,797	256,557	2,834,609	3,307,231	2,111,481
186.0700	1.32	Methoxyacetic acid	14,287,778	16,885,789	49,115,906	31,818,527	19,150,160
208.0972	3.32	Tryptophan	6,891,651	9,987,687	29,831,314	20,422,111	10,326,326
220.1179	3.23	Pantoic acid	9,895,816	13,643,744	40,736,131	22,840,905	14,547,263
258.1101	1.16	sn-Glyco-3-phosphocholine	1,968,194	158,879	4,045,000	6,744,707	2,306,900
268.1040	1.36	Adenosine	14,829,958	1,201,059	204,699,454	167,991,089	125,030,370
282.7791	1.03	10-oxo-10-oxo-octadecanamide	28,309,461	15,234,981	11,668,430	8,841,507	12,837,533
284.0883	1.50	Guanosine	1,085,113	0	812,105	73,595	6,793,688
291.1299	1.06	lL-argininobuccinate	0	0	1,972,395	2,238,552	55,244
298.0968	3.28	5-methylthioadenosine	1,048,514	860,940	6,602,083	3,850,328	2,365,072
302.3054	14.30	Sphinganine	1,022,641	893,474	5,106,193	4,845,628	2,796,139
310.1133	1.61	sn-3'-phosphoadenosine 3'-phosphate	8,448,576	7,959,759	8,567,921	7,795,346	9,868,218
400.3021	1.50	D-Pantoic acid	605,980	71,639	9,566,799	4,559,409	1,148,276
400.3085	1.65	l-10-oxo-10-oxo-octadecanamide	415,540	91,683	7,583,863	3,523,760	920,779
496.3998	25.46	1-Palmitoyl-1-acylglycerol-3-phosphocholine	627,315	251,763	2,033,967	1,204,991	1,056,461
502.2928	24.95	l-10-oxo-10-oxo-octadecanamide	180,527	604,338	1,994,431	1,534,697	391,022
522.3554	22.99	l-10-oxo-10-oxo-octadecanamide	47,719,221	49,893,245	61,051,126	51,484,131	59,509,071
523.0711	26.30	hexadecyl-2-acetyl-glycerol-3-phosphocholine	16,307,533	8,171,136	23,736,112	14,551,014	5,642,148

Table 2.
 Dependent upon the tumor cell line, the levels of several endogenous metabolites changed significantly. The table above shows a number of amino acids and lipids which change dependent on the cancer model and cell line [key; Calu corresponds to a non small cell lung cancer; SW, HCT, HT and COLO are colorectal tumors]. The identification of each component was verified using MS and MSn data to correlate mass accuracy and isotopic patterns with external data bases (such as <http://www.lipidmaps.org>; <http://www.hmdb.ca>; <http://www.genome.jp/kegg/>).




Figure 1.
 Principal component plot for the electrospray positive ion data (MS). Ion signals (or detected features) which resulted in a peak area variance of less than 30% were considered in this analysis (338 ion signals in total). [All results presented are for the organic extract].

Results




Figure 2.
 Levels of endogenous metabolites in the tumor extracts were compared between 2 different tumor bearing mice models (colorectal cancer [cell line HT-29; a cultured human colon cancer cell line] and non small lung cancer [cell line CALU6]). The differences are expressed as an average peak area value between the 2 groups.




Figure 3.
 Relative changes in the levels of phenylalanine and methionine for each cell line. To help visualize the changes in metabolite levels between each cell line the response has been normalized to the pooled QA sample. In the case of cell line HT29 the levels of phenylalanine and methionine were markedly higher than the other cell lines.

Discussion and Conclusion

Untargeted global metabolite profiling has been applied to analysis of endogenous metabolite levels in colorectal and non small cell lung cancer tumors implanted in mice. The changes in amino acid and lipid levels provide a useful framework to differentiate the human cell line tumors.
 • Endogenous metabolite levels have been measured and identified using high accuracy MS/MS data acquired on a LCMS-IT-TOF system and verified by reference to internal and external databases (<http://www.lipidmaps.org>;
<http://www.hmdb.ca>; <http://www.genome.jp/kegg/>).
 • The use of pooled samples in quality control has been recognized for some time but it lends itself well to profiling studies and PCA interpretation. In this study the pooled QC sample was used to characterize the reproducibility of the 'system'.
 • While the FDA suggests that variability of $\pm 15\%$ of the nominal value represents an acceptable degree of reproducibility, in long term profiling studies the tolerance is often relaxed to between 20-40%. In this study, ion signals which resulted in a relative standard deviation (RSD) <30% and retention time RSD <1% were considered in subsequent principal component analysis. (338 ion signals in ESI positive data and 467 ions were detected in negative ion).